Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
February 26, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
March 09, 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
October 19, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
Achillion Reports Second Quarter 2016 Financial Results
August 04, 2016 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
November 05, 2015 17:51 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
November 05, 2015 09:03 ET
|
Achillion Pharmaceuticals, Inc.
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...
Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference
November 02, 2015 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Reports Second Quarter and Six Month 2015 Financial Results
August 10, 2015 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2015. For the second...
$1.5 million gift to The Jackson Laboratory establishes Sims Family Fund for SMARD Research
August 05, 2015 16:08 ET
|
The Jackson Laboratory
BAR HARBOR, Maine, Aug. 5, 2015 (GLOBE NEWSWIRE) -- A $1.5 million gift to The Jackson Laboratory (JAX) from Mr. Grant Sims and Ms. Patricia (Patty) Sims of Houston, Texas, will fund research in a...